- Home
- QUAD vs LYEL Comparison
QUAD vs LYEL Comparison
Compare QUAD & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QUAD | LYEL |
|---|---|---|
| Founded | 1971 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.7M | 369.4M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | QUAD | LYEL |
|---|---|---|
| Price | $6.56 | $32.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $9.10 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 208.3K | 57.7K |
| Earning Date | 10-28-2025 | 11-12-2025 |
| Dividend Yield | ★ 4.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $2,497,700,000.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.28 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.50 | $7.65 |
| 52 Week High | $8.56 | $35.16 |
Technical Indicators
Market Signals| Indicator | QUAD | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 71.07 | 75.94 |
| Support Level | $6.01 | $20.59 |
| Resistance Level | $6.15 | $35.16 |
| Average True Range (ATR) | 0.20 | 2.56 |
| MACD | 0.09 | 1.05 |
| Stochastic Oscillator | 98.68 | 85.38 |
Price Performance
Historical ComparisonAbout QUAD Quad Graphics Inc
Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America and others countries. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market..
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.